Verve Therapeutics (VERV) said Monday its investigational new drug application for Verve-102 has been cleared by the US Food and Drug Administration to treat heterozygous familial hypercholesterolemia and/or premature coronary artery disease.
Verve-102 is an investigational in vivo base editing medicine that inactivates the PCSK9 gene in liver to reduce blood low-density lipoprotein cholesterol designed to be effective in one course of treatment, the company added.
The regulator's decision was based on the company's interim clinical data from the dose-escalation part of the current Heart-2 phase 1b clinical study for Verve-102, Verve said, adding that it intends to report demographic and initial safety and efficacy data from the Heart-2 clinical trial in Q2.
The company expects to post final data for the dose escalation portion of the Heart-2 clinical trial in H2.
Verve's stock was up 1.1% in recent Monday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.